Targovax AS, the Norwegian cancer vaccine company, today announced an important milestone in the ongoing clinical trial of its lead candidate TG01 for the treatment of operable pancreatic cancer. TG01 targets RAS mutations. The primary endpoint for the ongoing phase I/II clinical trial CT TG01-01, regarding immune response and side effects, has already been reached. Recruitment of patients for the clinical trial will now continue according to protocol and plan as a basis for the readout of secondary endpoints.
Contact:
Targovax
Jonas Einarsson, Chairman of the Board, cell phone: +47 48 09 63 55
E-mail: je@radforsk.no, (Press contact)
Hanne Mette D. Kristensen, CEO, cell phone: +47 97 19 74 49
E-mail: hmkristensen@targovax.com, web page www.targovax.com
Facts:
Targovax
Targovax was established in October in 2010 to develop immunotherapy in the form of therapeutic cancer vaccines based on pioneering research at the Norwegian Radium Hospital and Norsk Hydro. Mutation of RAS is an early mutation in the transformation of a normal cell into a cancer cell. Lead candidate TG01 educates the body’s immune system to recognize and kill cancer cells with RAS mutations. TG01 has Orphan Drug status for pancreatic cancer in the EU and US and is currently in Phase II trials in operated pancreatic cancer, patients start treatment up to 12 weeks after surgery. The company is located in Lysaker, close to Oslo, Norway.
Immuno- oncology / Cancer vaccines
The Norwegian cancer research community has been in the forefront of understanding the mechanisms for immuno-oncology and cancer vaccines. A cancer vaccine educates the body’s immune system to recognize and kill the cancer cells. The TG01 vaccine is therapeutic and is given as treatment to patients after surgery of cancer patients, to prevent relapse.
Pancreas cancer and other RAS-mutated cancer forms
Pancreatic cancer is a disease affecting 116 000 patients each year in EU and USA, and approximately 690 persons each year in Norway. Approx 15-20% of these are discovered at an early stage and are operable. The mortality is high, and the prognosis for these patients has been more or less unchanged the last 30 years. Approximately 80-90% of patients with pancreatic cancer have RAS mutations in the cancer cells.
RAS mutations occur in approx. 20% of all cancer cases, and are also frequent in colorectal cancer, non-small cell lung cancer and other cancers. Patients with RAS mutations within these indications have proved to be difficult to treat with current treatments, and there is a significant unmet medical need.
Help employers find you! Check out all the jobs and post your resume.
